ASCO 2020: Pevonedistat Shows Promise In Higher-Risk MDS
Remission Rates Double At Phase II
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
You may also be interested in...
The Phase III failure for pevonedistat in three rare blood cancer settings is the third setback for Takeda’s Wave 1 pipeline candidates this year. The NEDD8 inhibitor is still being studied in other settings.
The latest breakthrough therapy designation announcements from the Pink Sheet’s US FDA Performance Tracker
Japanese firm points to progress in its cancer pipeline as it looks to launch three new molecular entities in the sector by 2024 and investigates novel modalities.